Original Article

Identification and assessment of antifungal susceptibility of Candida species based on bronchoalveolar lavage in immunocompromised and critically ill patients

Abstract

Background and Objectives: The presence of fungi in the respiratory tract as mycobiome, particularly Candida species (spp.), remains a serious problem due to increasing numbers of immunocompromised pa-tients. The confirmed reliable existence of these pathogens due to frequent colonization is essential. This investigation aimed to recognize Candida spp. among isolates from bron-choalveolar lavage of immunocompromised and critically ill patients and to evaluate their susceptibility to antimycotic drugs.
Materials and Methods: Bronchoalveolar lavage fluid was collected from 161 hospitalized patients presenting with suspected respiratory fungal infection /colonization. The specimens were examined by standard molecular and mycological assays. Candida spp. were recognized with sequence assessment of the D1-D2 section of the large subunit ribosomal DNA. The susceptibility of Candida isolates to common antimycotic drugs was distinguished by standard broth micro-dilution.
Results: Seventy-one clinical isolates of Candida spp. were recognized. Candida albicans was the most frequent, followed by C. glabrata, C. krusei (Pichia kudriavzevii), C. dubliniensis, C. parapsilosis, and C. tropicalis. We found 5.1% of C. albicans isolates and 8% of C. glabrata isolates to show resistance to fluconazole. The whole of the Candida spp. were sensitive to amphotericin B and caspofungin.
Conclusion: This study demonstrated that C. albicans and C. glabrata are the most common isolates of bronchoalveolar lavage fluid in patients, and the drug susceptibility screening confirmed that amphotericin B and caspofungin are effective against Candida spp. but some C. glabrata and C. albicans isolates showed resistance to fluconazole.

1. Pendleton KM, Huffnagle GB, Dickson RP. The significance of Candida in the human respiratory tract: our evolving understanding. Pathog Dis 2017; 75: ftx029.
2. Knox KS, Meinke L. Role of bronchoalveolar lavage diagnostics in fungal infections. Clin Chest Med 2009; 30: 355-365.
3. Bille J, Marchetti O, Calandra T. Changing face of health-care associated fungal infections. Curr Opin Infect Dis 2005; 18: 314-319.
4. Nguyen LD, Viscogliosi E, Delhaes L. The lung mycobiome: an emerging field of the human respiratory microbiome. Front Microbiol 2015; 6: 89.
5. Nett JE, Zarnowski R, Cabezas-Olcoz J, Brooks EG, Berhardt J, Marchillo K, et al. Host contributions to construction of three device-associated Candida albicans biofilms. Infect Immun 2015; 83: 4630-4638.
6. Davidson KR, Ha DM, Schwarz MI, Chan ED. Bronchoalveolar lavage as a diagnostic procedure: a review of known cellular and molecular findings in various lung diseases. J Thorac Dis 2020; 12: 4991-5019.
7. Taghizadeh Armaki M, Hedayati MT, Mahdavi Omran S, Saber S, Abastabar M, Hosseinnejad A. Identification and antifungal susceptibility testing of Candida species isolated from bronchoalveolar lavage samples. Int J Mol Clin Microbiol 2014; 1: 358-364.
8. Déry MA, Hasbun R. Fluconazole-resistant Candida: mechanisms and risk factor identification. Curr Fungal Infect Rep 2011; 5: 23-28.
9. Lee Y, Puumala E, Robbins N, Cowen LE. Antifungal drug resistance: molecular mechanisms in Candida albicans and beyond. Chem Rev 2021; 121: 3390-3411.
10. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011; 71: 11-41.
11. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis 2020; 71: 1367-1376.
12. Zarrinfar H, Kaboli S, Dolatabadi S, Mohammadi R. Rapid detection of Candida species in bronchoalveolar lavage fluid from patients with pulmonary symptoms. Braz J Microbiol 2016; 47: 172-176.
13. Wood GC, Mueller EW, Croce MA, Boucher BA, Fabian TC. Candida sp. isolated from bronchoalveolar lavage: clinical significance in critically ill trauma patients. Intensive Care Med 2006; 32: 599-603.
14. Arbefeville S, Harris A, Ferrieri P. Comparison of sequencing the D2 region of the large subunit ribosomal RNA gene (MicroSEQ®) versus the internal transcribed spacer (ITS) regions using two public databases for identification of common and uncommon clinically relevant fungal species. J Microbiol Methods 2017; 140: 40-46.
15. Linton CJ, Borman AM, Cheung G, Holmes AD, Szekely A, Palmer MD, et al. Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United kingdom mycology reference laboratory. J Clin Microbiol 2007; 45: 1152-1158.
16. Clinical and laboratory standards institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. CLSI document M27 4th Edition; Clinical and Laboratory Standards Institute, Wayne, Pennsylvania. 2017.
17. Delisle M-S, Williamson DR, Perreault MM, Albert M, Jiang X, Heyland DK. The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients. J Crit Care 2008; 23: 11-17.
18. Kontoyiannis DP, Reddy BT, Torres HA, Luna M, Lewis RE, Tarrand J, et al. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis 2002; 34: 400-403.
19. Yan X, Zong F, Kong H, Wang Y, Zhao X, Liu W, et al. Pulmonary fungal diseases in immunocompetent hosts: a single-center retrospective analysis of 35 subjects. Mycopathologia 2016; 181: 513-521.
20. Chang W, Liu J, Zhang M, Shi H, Zheng S, Jin X, et al. Efflux pump-mediated resistance to antifungal compounds can be prevented by conjugation with triphenylphosphonium cation. Nat Commun 2018; 9: 5102.
21. Biernasiuk A, Malm A, Kiciak S, Tomasiewicz K. Susceptibility to antifungal drugs of Candida albicans isolated from upper respiratory tract of patients with chronic hepatitis C. J Pre Clin Clin Res 2013; 7: 111-113.
22. Badiee P, Badali H, Boekhout T, Diba K, Moghadam AG, Hossaini Nasab A, et al. Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates. BMC Infect Dis 2017; 17: 727.
23. Castanheira M, Deshpande LM, Davis AP, Rhomberg PR, Pfaller MA. Monitoring antifungal resistance in a global collection of invasive yeasts and moulds: application of CLSI epidemiological cutoff values and whole genome sequencing analysis for detection of azole resistance in Candida albicans. Antimicrob Agents Chemother 2017; 61(10): e00906-17.
24. Taghipour S, Rezaei-Matehkolaei A, Zarei Mahmoudabadi A. Antifungal susceptibility profiles of Candida species isolated from Ahvaz Jundishapur educational hospitals. Jundishapur J Microbiol 2018; 11(11): e78851.
25. Shahin J, Allen EJ, Patel K, Muskett H, Harvey SE, Edgeworth J, et al. Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units. BMC Infect Dis 2016; 16: 480.
26. Fracchiolla NS, Sciumè M, Orofino N, Guidotti F, Grancini A, Cavalca F, et al. Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a single-centre study. PLoS One 2019; 14(5): e0216715.
Files
IssueVol 16 No 2 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v16i2.15362
Keywords
Bronchoalveolar lavage; Candida albicans; Candida glabrata; Immunocompromised patient; Fluconazole; Amphotericin‌ B
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Rezaei R, Aliannejad R, Falahati M, Ghasemi Z, Ashrafi-Khozani M, Fattahi M, Razavi T, Farahyar S. Identification and assessment of antifungal susceptibility of Candida species based on bronchoalveolar lavage in immunocompromised and critically ill patients. Iran J Microbiol. 2024;16(2):273-279.